首页> 外文期刊>Cancer biology & therapy >PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: kinase activity profiling as powerful tool in functional studies.
【24h】

PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: kinase activity profiling as powerful tool in functional studies.

机译:PTK787 / ZK 222584抑制肿瘤生长,促进间充质干细胞:激酶活性分析是功能研究中的强大工具。

获取原文
获取原文并翻译 | 示例
           

摘要

Bone marrow (BM)-derived mesenchymal stem cells (MSCs) have been shown to favor tumor growth, suggesting the relevance of pharmaceutical inhibition of MSCs for the treatment of malignancies. We tested the effect of PTK787/ZK 222584 (PTK) on the outgrowth of MSCs from human bone marrow-derived mononuclear cells (MNCs) and the migration and tube formation capacity of MSCs in vitro. PTK dose-dependently inhibited the outgrowth of BM-MSCs from BM-MNCs (LC50 1.12 microM PTK), while hematopoietic colony formation (HCF) was only slightly hampered (13 +/- 19% at 1 microM PTK, and stable at approximately 50% at higher concentrations of PTK). Addition of 10 microM PTK inhibited proliferation of MSCs by 74 +/- 6.6% compared to control (p < 0.0001) and increased apoptosis of MSCs by 63 +/- 7.7% (p < 0.01). In addition, upon addition of PTK, BM-MSCs showed impaired tube formation as well as reduced migration (52 +/- 19%, p = 0.006) compared to control. Pepchip array analysis revealed that PTK effectively inhibits activity of kinases involved in cell cycling (WEE1 and several cyclin dependent kinases), and migratory processes (including Rho kinase). In conclusion, we show that PTK impairs outgrowth, proliferation, migration and tube formation of human BM-MSCs. In addition, we show the usability of Pepchip array analysis as a powerful tool for kinase activity profiling in functional studies since the effect of PTK on the kinome profile of MSCs corresponds with the observed functional effects of PTK on proliferation and migration. Inhibition of BM-MSCs and their contribution to tumor growth may be an additional strategy for treatment of cancer in the future.
机译:骨髓(BM)来源的间充质干细胞(MSCs)已显示出有利于肿瘤生长,表明MSCs的药物抑制作用与恶性肿瘤治疗具有相关性。我们测试了PTK787 / ZK 222584(PTK)对人骨髓衍生单核细胞(MNC)产生的MSC的生长以及体外MSC迁移和管形成能力的影响。 PTK剂量依赖性地抑制了BM-MSC从BM-MNC的生长(LC50 1.12 microM PTK),而造血菌落形成(HCF)仅受到轻微的阻碍(1 microM PTK时为13 +/- 19%,稳定在大约50 %在较高的PTK浓度下)。与对照相比,添加10 microM PTK抑制MSC的增殖达74 +/- 6.6%(p <0.0001),并使MSC的凋亡增加63 +/- 7.7%(p <0.01)。另外,与对照相比,加入PTK后,BM-MSCs显示出受损的管形成以及迁移减少(52 +/- 19%,p = 0.006)。 Pepchip阵列分析显示,PTK有效抑制细胞周期中涉及的激酶(WEE1和几种细胞周期蛋白依赖性激酶)和迁移过程(包括Rho激酶)的活性。总之,我们表明PTK会损害人BM-MSC的生长,增殖,迁移和管形成。此外,我们显示Pepchip阵列分析可作为功能研究中激酶活性分析的强大工具,因为PTK对MSCs的基因组谱的影响与PTK对增殖和迁移的功能影响相对应。抑制BM-MSC及其对肿瘤生长的贡献可能是将来治疗癌症的另一种策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号